PH12018500363A1 - Bispecific monovalent diabodies that are capable of binding b7-h3 and cd3, and uses thereof - Google Patents

Bispecific monovalent diabodies that are capable of binding b7-h3 and cd3, and uses thereof

Info

Publication number: PH12018500363A1
Authority: PH; Philippines
Prior art keywords: diabodies; bispecific monovalent; binding; monovalent diabodies; directed
Prior art date: 2015-08-17

Application number

PH12018500363A

Other languages

English (en)

Inventor

Leslie S Johnson

Paul A Moore

Ezio Bonvini

Ling Huang

Kalpana Shah

Ralph Alderson

Gurunadh Reddy Chichili

Original Assignee

Macrogenics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-08-17

Filing date

2018-02-15

Publication date

2018-09-10

2018-02-15 Application filed by Macrogenics Inc filed Critical Macrogenics Inc

2018-09-10 Publication of PH12018500363A1 publication Critical patent/PH12018500363A1/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Immunology (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

PH12018500363A 2015-08-17 2018-02-15 Bispecific monovalent diabodies that are capable of binding b7-h3 and cd3, and uses thereof PH12018500363A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201562206051P	2015-08-17	2015-08-17
US201662280318P	2016-01-19	2016-01-19
PCT/US2016/046680 WO2017030926A1 (en)	2015-08-17	2016-08-12	Bispecific monovalent diabodies that are capable of binding b7-h3 and cd3, and uses thereof

Publications (1)

Publication Number	Publication Date
PH12018500363A1 true PH12018500363A1 (en)	2018-09-10

Family

ID=58051498

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PH12018500363A PH12018500363A1 (en)	2015-08-17	2018-02-15	Bispecific monovalent diabodies that are capable of binding b7-h3 and cd3, and uses thereof

Country Status (21)

Country	Link
US (1)	US20190002563A1 (es)
EP (1)	EP3337507A4 (es)
JP (1)	JP2018523686A (es)
KR (1)	KR20180038045A (es)
CN (1)	CN107921130A (es)
AU (1)	AU2016307955A1 (es)
CA (1)	CA2995709A1 (es)
CL (1)	CL2018000422A1 (es)
CO (1)	CO2018001485A2 (es)
CR (1)	CR20180105A (es)
EA (1)	EA201890443A1 (es)
EC (1)	ECSP18011248A (es)
HK (1)	HK1249423A1 (es)
IL (1)	IL257562A (es)
MA (1)	MA42665A (es)
MX (1)	MX2018001954A (es)
PE (1)	PE20181066A1 (es)
PH (1)	PH12018500363A1 (es)
TW (1)	TW201718652A (es)
WO (1)	WO2017030926A1 (es)
ZA (1)	ZA201800955B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG10201913324PA (en)	2014-05-29	2020-03-30	Macrogenics Inc	Tri-specific binding molecules and methods of use thereof
TWI706960B (zh) *	2014-09-26	2020-10-11	美商宏觀基因股份有限公司	能夠結合cd19和cd3的雙特異性雙抗體及其用途
AU2016370376B2 (en)	2015-12-14	2023-12-14	Macrogenics, Inc.	Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
BR112019017628A2 (pt)	2017-02-24	2020-07-07	Macrogenics, Inc.	molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
KR20240165484A (ko)	2017-04-11	2024-11-22	인히브릭스 바이오사이언스, 인크.	제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 이를 이용한 방법
IL302613B2 (en) *	2017-09-08	2025-04-01	Maverick Therapeutics Inc	Binding proteins are activated under limited conditions
CN109939231A (zh) *	2017-12-21	2019-06-28	张曼	关于cd3×b7h3双特异性抗体定向杀伤膀胱癌细胞t24的应用
CN109939230A (zh) *	2017-12-21	2019-06-28	张曼	关于cd3×b7h3双特异性抗体定向杀伤耐顺铂膀胱癌细胞t24/ddp的应用
CN109939232A (zh) *	2017-12-21	2019-06-28	张曼	关于cd3×b7h3双特异性抗体定向杀伤膀胱癌细胞pumc-91的应用
CN109939126A (zh) *	2017-12-21	2019-06-28	张曼	Cd3×b7h3双特异抗体定向杀伤耐阿霉素膀胱癌细胞pumc-91/adm的应用
CN109971711A (zh) *	2017-12-27	2019-07-05	张曼	关于cd3×b7h3双特异性抗体定向杀伤人膀胱癌细胞的应用
AU2019222666B2 (en)	2018-02-15	2025-12-04	Macrogenics, Inc.	Variant CD3-binding domains and their use in combination therapies for the treatment of disease
EP3773913A1 (en)	2018-04-11	2021-02-17	Inhibrx, Inc.	Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses
TWI848953B (zh)	2018-06-09	2024-07-21	德商百靈佳殷格翰國際股份有限公司	針對癌症治療之多特異性結合蛋白
US12195533B2 (en)	2018-07-24	2025-01-14	Inhibrx Biosciences, Inc.	Multispecific polypeptide constructs containing a constrained CD3 binding domain and a receptor binding region and methods of using the same
CN109762068A (zh) *	2018-08-09	2019-05-17	源道隆（苏州）医学科技有限公司	一种可靶向ctla4和pd-1的单基因双特异性抗体及其应用
EP3864049A1 (en)	2018-10-11	2021-08-18	Inhibrx, Inc.	Pd-1 single domain antibodies and therapeutic compositions thereof
JP2022512684A (ja)	2018-10-11	2022-02-07	インヒブルクスインコーポレイテッド	Ｂ７ｈ３シングルドメイン抗体およびその治療用組成物
TW202033218A (zh) *	2018-12-07	2020-09-16	大陸商江蘇恆瑞醫藥股份有限公司	多特異性蛋白分子
TWI821474B (zh) *	2018-12-07	2023-11-11	大陸商江蘇恆瑞醫藥股份有限公司	Ｃｄ３抗體及其藥物用途
KR102732027B1 (ko) *	2019-07-09	2024-11-20	주식회사 와이바이오로직스	B7-h3(cd276)에 특이적으로 결합하는 항체 및 그의 용도
CN111454357B (zh) *	2019-08-14	2022-03-15	康诺亚生物医药科技（成都）有限公司	一种含有抗体的肿瘤治疗剂的开发和应用
EP3822288A1 (en) *	2019-11-18	2021-05-19	Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts	Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof
JP2023507848A (ja) *	2019-12-23	2023-02-27	マクロジェニクス，インコーポレーテッド	癌の治療のための療法
IL294879A (en)	2020-01-29	2022-09-01	Inhibrx Inc	Cd28 single domain antibodies and multivalent and multispecific constructs thereof
CN117751145A (zh) *	2021-04-28	2024-03-22	礼进生物医药科技（上海）有限公司	包括抗b7h3结合分子的双特异性抗体
CN113527493B (zh) *	2021-07-20	2023-10-27	广州爱思迈生物医药科技有限公司	一种b7-h3抗体及其应用
WO2023086772A1 (en)	2021-11-12	2023-05-19	Xencor, Inc.	Bispecific antibodies that bind to b7h3 and nkg2d
CN114539420B (zh) *	2022-01-20	2024-05-17	荣昌生物制药(烟台)股份有限公司	抗b7-h3单克隆抗体、抗b7-h3×cd3双特异性抗体、制备方法及其应用
CN117903311B (zh) *	2024-03-20	2024-10-25	湖南卓润生物科技有限公司	sST2特异性结合蛋白及其制备方法和应用
WO2025245264A1 (en) *	2024-05-21	2025-11-27	Briapro Therapeutics Corp.	Anti-b7-h3 antibodies and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG10201604336VA (en) *	2010-03-04	2016-07-28	Macrogenics Inc	Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof
BR112013029893A2 (pt) *	2011-05-21	2017-05-30	Macrogenics Inc	molécula de ligação a cd3, anticorpo de ligação a cd3, diacorpo de ligação a cd3 e composição farmacêutica
US10851178B2 (en) *	2011-10-10	2020-12-01	Xencor, Inc.	Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US9487587B2 (en) *	2013-03-05	2016-11-08	Macrogenics, Inc.	Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
US20140302037A1 (en) *	2013-03-15	2014-10-09	Amgen Inc.	BISPECIFIC-Fc MOLECULES
UA116479C2 (uk) *	2013-08-09	2018-03-26	Макродженікс, Інк.	БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
EP2839842A1 (en) *	2013-08-23	2015-02-25	MacroGenics, Inc.	Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
RU2731202C2 (ru) *	2015-10-08	2020-08-31	Макродженикс, Инк.	Комбинированная терапия для лечения рака

2016
- 2016-08-12 KR KR1020187007443A patent/KR20180038045A/ko not_active Withdrawn
- 2016-08-12 CN CN201680048182.7A patent/CN107921130A/zh active Pending
- 2016-08-12 MA MA042665A patent/MA42665A/fr unknown
- 2016-08-12 PE PE2018000249A patent/PE20181066A1/es unknown
- 2016-08-12 CR CR20180105A patent/CR20180105A/es unknown
- 2016-08-12 EA EA201890443A patent/EA201890443A1/ru unknown
- 2016-08-12 CA CA2995709A patent/CA2995709A1/en not_active Abandoned
- 2016-08-12 WO PCT/US2016/046680 patent/WO2017030926A1/en not_active Ceased
- 2016-08-12 JP JP2018508741A patent/JP2018523686A/ja active Pending
- 2016-08-12 MX MX2018001954A patent/MX2018001954A/es unknown
- 2016-08-12 EP EP16837560.8A patent/EP3337507A4/en not_active Withdrawn
- 2016-08-12 HK HK18109035.8A patent/HK1249423A1/zh unknown
- 2016-08-12 AU AU2016307955A patent/AU2016307955A1/en not_active Abandoned
- 2016-08-12 US US15/752,367 patent/US20190002563A1/en not_active Abandoned
- 2016-08-16 TW TW105126154A patent/TW201718652A/zh unknown
2018
- 2018-02-13 ZA ZA2018/00955A patent/ZA201800955B/en unknown
- 2018-02-15 EC ECIEPI201811248A patent/ECSP18011248A/es unknown
- 2018-02-15 CO CONC2018/0001485A patent/CO2018001485A2/es unknown
- 2018-02-15 PH PH12018500363A patent/PH12018500363A1/en unknown
- 2018-02-15 CL CL2018000422A patent/CL2018000422A1/es unknown
- 2018-02-15 IL IL257562A patent/IL257562A/en unknown

Also Published As

Publication number	Publication date
CO2018001485A2 (es)	2018-07-10
KR20180038045A (ko)	2018-04-13
PE20181066A1 (es)	2018-07-04
MX2018001954A (es)	2018-11-09
HK1249423A1 (zh)	2018-11-02
JP2018523686A (ja)	2018-08-23
WO2017030926A1 (en)	2017-02-23
EP3337507A1 (en)	2018-06-27
EA201890443A1 (ru)	2018-09-28
US20190002563A1 (en)	2019-01-03
MA42665A (fr)	2018-06-27
CN107921130A (zh)	2018-04-17
AU2016307955A1 (en)	2018-03-08
TW201718652A (zh)	2017-06-01
CA2995709A1 (en)	2017-02-23
CL2018000422A1 (es)	2018-08-10
ECSP18011248A (es)	2018-04-30
ZA201800955B (en)	2018-11-28
IL257562A (en)	2018-04-30
CR20180105A (es)	2018-06-12
EP3337507A4 (en)	2019-04-24

Publication	Publication Date	Title
PH12018500363A1 (en)	2018-09-10	Bispecific monovalent diabodies that are capable of binding b7-h3 and cd3, and uses thereof
PH12019500923A1 (en)	2019-08-19	Anti-pd-1 antibodies and compositions
MX2018003936A (es)	2018-07-06	Anticuerpos anti proteina de muerte celular programada 1 (pd-1) y composiciones.
PH12018502429A1 (en)	2019-09-30	Antibody molecules for cancer treatment
MY203971A (en)	2024-07-26	Anti-lag-3 antibodies and compositions
MX2020012797A (es)	2021-03-25	Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
ZA201708265B (en)	2025-04-30	Tigit-binding agents and uses thereof
MD20170040A2 (ro)	2017-07-31	Diacorpi monovalenţi bispecifici capabili de legare cu CD19 şi CD3 şi utilizarea acestora
TN2016000046A1 (en)	2017-07-05	Bi-specific monovalent diabodies that are capable of binding cd123 and cd3, and uses therof
EP4417263A3 (en)	2024-11-20	Cd3 binding antibodies
PH12016500291B1 (en)	2016-05-02	Bi-specific monovalent diabodies that are capable of binding to gpa33 and cd3, and uses thereof
MX2017000187A (es)	2017-06-30	Proteinas de union a cd33 y cd3 biespecificas.
MY192392A (en)	2022-08-18	Chimeric antigen receptors targeting bcma and methods of use thereof
PH12017501748B1 (en)	2024-01-17	Antibodies to icos
EP4249515A3 (en)	2023-11-15	Humanized or chimeric cd3 antibodies
GEP20227343B (en)	2022-01-25	Anti-lag3 antibodies and antigen-binding fragments
MX2018010295A (es)	2019-06-06	Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
MX2017003247A (es)	2017-11-30	Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas.
MX2017015380A (es)	2018-03-28	Metodos para utilizar proteinas de enlace biespecificas cd3 y cd33.
MX2015011518A (es)	2016-02-03	Agentes de enlace de met y usos de los mismos.
MX2024005841A (es)	2024-05-27	Moleculas de union a cd32b x cd79b para usarse como medicamentos para el tratamiento de enfermedades o trastornos inflamatorios y para reducir las respuestas inmunitarias.
TW201613977A (en)	2016-04-16	Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MA40363A (fr)	2017-06-21	Agents de liaison de rspo1 et leurs utilisations
AR105714A1 (es)	2017-11-01	Diacuerpos monovalentes biespecíficos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos
NZ771777A (en)	2024-11-29	Bispecific antibodies against cd3 and cd20